200 related articles for article (PubMed ID: 28234344)
1. Mutational landscape reflects the biological continuum of plasma cell dyscrasias.
Rossi A; Voigtlaender M; Janjetovic S; Thiele B; Alawi M; März M; Brandt A; Hansen T; Radloff J; Schön G; Hegenbart U; Schönland S; Langer C; Bokemeyer C; Binder M
Blood Cancer J; 2017 Feb; 7(2):e537. PubMed ID: 28234344
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.
Testa S; Kumar J; Goodell AJ; Zehnder JL; Alexander KM; Sidana S; Arai S; Witteles RM; Liedtke M
Semin Oncol; 2022 Dec; 49(6):465-475. PubMed ID: 36503855
[TBL] [Abstract][Full Text] [Related]
3. Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias.
Rebmann Chigrinova E; Porret NA; Andres M; Wiedemann G; Banz Y; Legros M; Pollak M; Oppliger Leibundgut E; Pabst T; Bacher U
BMC Med Genomics; 2022 Sep; 15(1):203. PubMed ID: 36138464
[TBL] [Abstract][Full Text] [Related]
4. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
5. N- and K-ras oncogenes in plasma cell dyscrasias.
Corradini P; Ladetto M; Inghirami G; Boccadoro M; Pileri A
Leuk Lymphoma; 1994 Sep; 15(1-2):17-20. PubMed ID: 7858496
[TBL] [Abstract][Full Text] [Related]
6. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
Lionetti M; Barbieri M; Manzoni M; Fabris S; Bandini C; Todoerti K; Nozza F; Rossi D; Musto P; Baldini L; Neri A
Oncotarget; 2016 Apr; 7(16):21353-61. PubMed ID: 26870891
[TBL] [Abstract][Full Text] [Related]
7. A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Fabris S; Tonon G; Segalla S; Cifola I; Pinatel E; Tassone P; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(28):26129-41. PubMed ID: 26305418
[TBL] [Abstract][Full Text] [Related]
8. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
9. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.
Kim SJ; Shin HT; Lee HO; Kim NK; Yun JW; Hwang JH; Kim K; Park WY
Oncotarget; 2016 Oct; 7(42):68350-68359. PubMed ID: 27634910
[TBL] [Abstract][Full Text] [Related]
10. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
[TBL] [Abstract][Full Text] [Related]
12. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
[TBL] [Abstract][Full Text] [Related]
13. Analysis of chromosome 12p deletion in plasma cell dyscrasias.
Jiang N; Qi C; Yu L; Ning Y; An G; Qiu L; Chang H
Leuk Res; 2012 Jan; 36(1):32-6. PubMed ID: 21982640
[TBL] [Abstract][Full Text] [Related]
14. State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias.
Amini B; Yellapragada S; Shah S; Rohren E; Vikram R
Radiol Clin North Am; 2016 May; 54(3):581-96. PubMed ID: 27153790
[TBL] [Abstract][Full Text] [Related]
15. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
Bacher U; Haferlach T; Kern W; Alpermann T; Schnittger S; Haferlach C
Cancer Genet Cytogenet; 2010 Dec; 203(2):169-75. PubMed ID: 21156229
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
[TBL] [Abstract][Full Text] [Related]
17. Human herpesvirus 8 genome is not found in whole bone marrow core biopsy specimens of patients with plasma cell dyscrasias.
Drabick JJ; Davis BJ; Lichy JH; Flynn J; Byrd JC
Ann Hematol; 2002 Jun; 81(6):304-7. PubMed ID: 12107558
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
Corradini P; Inghirami G; Astolfi M; Ladetto M; Voena C; Ballerini P; Gu W; Nilsson K; Knowles DM; Boccadoro M
Leukemia; 1994 May; 8(5):758-67. PubMed ID: 8182933
[TBL] [Abstract][Full Text] [Related]
19. Compendium of FAM46C gene mutations in plasma cell dyscrasias.
Barbieri M; Manzoni M; Fabris S; Ciceri G; Todoerti K; Simeon V; Musto P; Cortelezzi A; Baldini L; Neri A; Lionetti M
Br J Haematol; 2016 Aug; 174(4):642-5. PubMed ID: 26456599
[No Abstract] [Full Text] [Related]
20. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]